Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104
The new patent, covering RHB-104 for relapsing-remitting multiple sclerosis (MS), is expected to be valid until 2032, once granted Enrollment in the Phase III study with RHB-104 for Crohn's disease to be completed in November 2017 and top-line results expected in Q3/2018 A pivotal Phase III study ...
View HTML
Toggle Summary RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer
RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if approved   MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with ...
View HTML
Toggle Summary RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 19, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
View HTML
Toggle Summary RedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 10, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
BEKINDA ® i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan ® (rifaximin) and Viberzi ® (eluxadoline) ...
View HTML
Toggle Summary RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn's Disease with Top-Line Results Expected Mid-2018
RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB-104 for Crohn's disease (MAP US) from 410 to approximately 325 subjects, of which 322 have been enrolled to date, while maintaining statistical power of over 80% with a treatment effect of 15%   A review of ...
View HTML
Toggle Summary RedHill Biopharma to Announce Top-Line Results from BEKINDA® 12 mg Phase II Study for IBS-D on October 3rd, 2017
TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of ...
View HTML
Toggle Summary RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers
TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of ...
View HTML
Toggle Summary RedHill Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of ...
View HTML
Toggle Summary RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.
Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA -approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal ( GI) conditions   PPIs are one of the most commonly ...
View HTML